Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study aimed at evaluating whether current 24 weeks length of combination treatment is appropriate or not for patients with HCV genotype 3 infection.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Casa Sollievo della Sofferenza IRCCS
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons; Peginterferon alfa-2b; Ribavirin

Criteria

Inclusion Criteria:

• Naive HCV patients

• HCVRNA positive

• Normal TSH

• ANA <1:160

Exclusion Criteria:

• Portal hypertension

• Renal failure

• HBsAg or HIV

• Alcohol consumption >30 g/day

• Active IV drug use

• Chronic systemic diseases